MEX3D and non-small cell lung carcinoma: Overexpression of MEX3A, MEX3B and MEX3D were associated with a significantly worse prognosis for NSCLC patients: MEX3A (HR = 1.48; CI 1.26–1.75; P = 2.9E−06), MEX3B (HR = 1.37; CI 1.17–1.62; P = 1.4E−04) and MEX3D (HR = 1.30; CI 1.14–1.47; P = 5.2E−05).